Lv1
30 积分 2025-02-18 加入
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
1个月前
已完结
G protein-coupled estrogen receptor biased signaling in health and disease
3个月前
已完结
Systematic characterization of m6A proteomics across 12 cancer types: a multi-omics integration study
3个月前
已完结
Hallmarks of cancer—Then and now, and beyond
3个月前
已完结
皖公网安备34019202002308
